Biofrontera Employees

As of December 31, 2025, Biofrontera had 94 total employees, including 84 full-time and 10 part-time employees. The number of employees increased by 1 or 1.08% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

1.08%

Revenue / Employee

$443,670

Profits / Employee

-$112,085

Market Cap

13.05M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	94	1	1.08%
Dec 31, 2024	93	8	9.41%
Dec 31, 2023	85	4	4.94%
Dec 31, 2022	81	12	17.39%
Dec 31, 2021	69	13	23.21%
Dec 31, 2020	Pro	Pro	Pro

Related Stocks

Company Name	Employees
China Pharma Holdings	215
Aytu BioPharma	83
China SXT Pharmaceuticals	75
cbdMD	42
BioXcel Therapeutics	29
Gelteq	8
Caring Brands	4
Shuttle Pharmaceuticals Holdings	2

Employee Rankings

BFRI News

5 weeks ago - Biofrontera Earnings Call Transcript: Q4 2025 - Transcripts
5 weeks ago - Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
7 weeks ago - Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - GlobeNewsWire
7 weeks ago - Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - GlobeNewsWire
2 months ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
2 months ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
2 months ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
2 months ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire

More News